Cantor Fitzgerald reiterated their overweight rating on shares of Disc Medicine (NASDAQ:IRON – Free Report) in a research report released on Tuesday morning, Benzinga reports. The firm currently has a $85.00 price objective on the stock. Several other equities research analysts also recently commented on the company. Morgan Stanley reduced their target price on Disc […]
Cantor Fitzgerald reissued their overweight rating on shares of Disc Medicine (NASDAQ:IRON – Free Report) in a report issued on Tuesday morning, Benzinga reports. They currently have a $85.00 target price on the stock. IRON has been the subject of a number of other reports. Wedbush reaffirmed an outperform rating and set a $43.00 price […]
Disc Medicine, Inc. (NASDAQ:IRON – Get Free Report) Director William Richard White sold 2,560 shares of the firm’s stock in a transaction that occurred on Thursday, April 11th. The stock was sold at an average price of $31.80, for a total value of $81,408.00. The transaction was disclosed in a document filed with the SEC, […]
Wedbush restated their outperform rating on shares of Disc Medicine (NASDAQ:IRON – Free Report) in a research report released on Monday morning, RTT News reports. The brokerage currently has a $43.00 target price on the stock, down from their prior target price of $84.00. Wedbush also issued estimates for Disc Medicine’s Q4 2024 earnings at […]
Raymond James restated their outperform rating on shares of Disc Medicine (NASDAQ:IRON – Free Report) in a research report sent to investors on Monday, MarketBeat Ratings reports. Raymond James currently has a $40.00 target price on the stock, down from their prior target price of $75.00. IRON has been the subject of several other reports. […]